

Fact Sheet

Investor Relations
Tel.: ++ 386 7 331 2287
Fax: ++ 386 7 332 1523
e-mail: finance@krka.biz




Living a healthy life.

June 2010

website: www.krka.biz

- One of the leading generic pharmaceutical companies in the world with over 50 years of experience in the industry and strong focus on branded generic prescription pharmaceuticals (Rx).
- Extensive Rx portfolio supplemented by self-medication (OTC), animal health, cosmetic products and health & tourism services (Terme Krka).
- Serving customers in more than 70 markets.
- Headquartered in Slovenia with production & distribution facilities in Slovenia, Poland, Croatia, Russia and in Germany.

Group Net Sales & Profit (€ Millions)




- For 2010 Krka Group plans to achieve sales of € 1,008 million, net profit of € 159 million and investment expenditure of € 176 million.
- In 2010–2014 we are planning to achieve average annual sales growth above industry average.

Future Growth Prospects

- Focus on marketing and further development of own marketing & sales network.
- Pursuing economics of scale.
- Major patent expiries of blockbuster drugs.
- Convergence of medicines expenditure per capita towards higher, western levels on our key markets.
- Global generic market growth due to governments' health care cost saving efforts.
- Emergence of new generic markets.


Total group sales 2009 € 953 Million




Strategic Focus

- Prioritising European and central Asian markets.
- Prioritising the strengthening of the pharmaceutical and chemical activities.
- Strengthening the competitive advantage of the product portfolio by maintaining the highest possible share of vertical integrated products and launching selected products as the first generic on selected key markets.
- Developing generic medicines and preparing market authorisation documentation before the expiry of the product patent for the original medicine.
- Strengthening competitiveness on western European markets by establishing its own marketing companies.
- Strengthening synergy within the Krka Group (in expertise and costs).
- Restructuring the purchasing market to ensure the continual reduction of purchase prices.
- Pursuing a moderate dividend increase policy.
- Continued growth of market shares through the purchase of local pharmaceutical companies or business acquisition on selected markets.
- Maintaining our economic, social and protection responsibilities for the environment in which we operate.
- Maintaining independence.

Group sales by regions in 1Q 2010 (€ Millions)



Group sales by segment in 1Q 2010 (€ Millions)




New Product Development

- In 1Q 2010 we acquired first market authorisations for 4 new products in 12 pharmaceutical forms and 220 new market authorisations across a number of different markets.
- In 2009, Krka received first marketing authorisations for 21 new products in 40 pharmaceutical forms and a total of 874 new marketing authorisations.
- Acquisition of marketing authorisation for two products with clopidogrel API.
- Nimvastid (rivastigmine) for Alzheimer's in 2 pharmaceutical forms. Krka is the only supplier of this product in orodispersible form.
- CP procedure providing EU-wide market authorisations was successfully concluded for Vizarsin, a generic version of sildenafil for treatment of erectile dysfunction.

Share Listing

- Krka is the most liquid share with the highest market capitalization on the Ljubljana Stock Exchange.
- Share split executed on 3 September 2007 (10 shares for 1 existing).
- Market capitalisation of approximately € 2.4 Billion.

Share performance relative to comparable indices



Stock Market Data

as of 7 June 2010 (in €)

Stock Symbol:	KRKG
Recent share price:	66.41
Market Capitalization:	2.35 Billion
52 - week range:	76.17 — 63.09

Home page

<http://www.krka.biz/en/finance/>

For additional information, contact:

Krka, d. d., Novo mesto
Finance Division
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Tel: + 386 7 331 2287
Fax: + 386 7 332 1523
e-mail: finance@krka.biz

Additional information